Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

OKT3 prophylaxis improves long-term renal graft survival in high-risk patients as compared to cyclosporine: combined results from the prospective, randomized Belgian and US studies.

Abramowicz D, Norman DJ, Goldman M, De Pauw L, Kinnaert P, Kahana L, Thistlethwaite JR, Shield CF, Monaco AP, Vanherweghem JL, et al. OKT3 prophylaxis improves long-term renal graft survival in high-risk patients as compared to cyclosporine: combined results from the prospective, randomized Belgian and US studies. Transplant Proc. 1995 Feb; 27(1):852-3.

View in: PubMed

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.